BRIEF-Pepgen Announces Update To Phase 2 Connect2-Edo51 Study In Patients With DMD

Reuters
04 Mar
BRIEF-Pepgen Announces Update To Phase 2 Connect2-Edo51 Study In Patients With DMD

March 4 (Reuters) - PepGen Inc PEPG.O:

  • PEPGEN ANNOUNCES UPDATE TO PHASE 2 CONNECT2-EDO51 STUDY IN PATIENTS WITH DMD

  • PEPGEN INC - TO PAUSE PHASE 2 CONNECT2-EDO51 STUDY IN DMD PATIENTS

  • PEPGEN INC - DATA FROM 10 MG/KG COHORT EXPECTED IN Q3 2025

  • PEPGEN INC: WILL FOCUS EFFORTS ON ONGOING CONNECT1-EDO51 STUDY OF PGN-EDO51 IN DMD

  • PEPGEN INC - NO NEW SAFETY ISSUES OBSERVED IN PGN-EDO51 PROGRAM

Source text: ID:nBw1spcTNa

Further company coverage: PEPG.O

(Reuters.Briefs@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10